CAR-T Technology
ICT is building a comprehensive platform of CAR-T products
ICT is building a comprehensive platform of CAR-T products for blood cancers and solid tumors, including an allogeneic CAR-T development program. CAR-T therapies of the future will combine stem cells, gene editing and gene therapy, and ICT is making breakthroughs to combine these technologies, including advances in leveraging hematopoietic stem cells.
Chimeric Antigen Receptor T-cells (CAR-T) are created by coupling the antigen-binding site of a tumor-recognizing antibody and the intracellular signaling domain of a T-cell of a patient through gene transduction, so that the cell expresses CAR. After being recoded, the T-cells of the patient are able to generate a large quantity of tumor-specific CAR-T cells.
